What is Monod Bio?
Monod Bio is a Seattle, Washington-based startup focused on the development of advanced biosensors. These innovative devices are engineered to detect a wide range of critical molecules, including antibodies, toxins, and viral proteins. By providing precise and rapid detection capabilities, Monod Bio aims to revolutionize diagnostics and monitoring across various sectors, from healthcare to environmental safety. The company's technology addresses a growing need for sensitive and specific molecular detection tools.
How much funding has Monod Bio raised?
Monod Bio has raised a total of $31M across 2 funding rounds:
Angel/Seed
$6M
Angel/Seed
$25M
Angel/Seed (2021): $6M, investors not publicly disclosed
Angel/Seed (2022): $25M led by Matrix Capital Advisors, Washington Research Foundation, Boom Capital Ventures, Global Health Investment Corporation, and Cercano Management
Key Investors in Monod Bio
Washington Research Foundation
Washington Research Foundation is a key supporter of life sciences and enabling technologies in Washington state, focusing on commercializing university research and investing in early-stage local companies.
Matrix Capital Advisors
Matrix Capital Advisors is an investment firm that offers wealth management and customized investment solutions, likely evaluating Monod Bio's potential for significant financial returns.
Boom Capital Ventures
Boom Capital Ventures is an undisclosed investor participating in the funding round, indicating a strategic interest in Monod Bio's growth trajectory.
What's next for Monod Bio?
With the recent influx of major strategic investment, Monod Bio is poised for an accelerated growth phase. This capital infusion is expected to fuel further research and development, enhance manufacturing capabilities, and expand market reach. The company's focus on biosensor technology positions it to capitalize on the increasing demand for rapid and accurate molecular diagnostics. Future endeavors will likely involve scaling operations, forging strategic partnerships, and potentially pursuing further funding rounds to support long-term expansion and commercialization efforts.
See full Monod Bio company page
